The objective of this two day "Essentials of USP Microbiology" seminar is to explore USP General and General Information Chapters to learn which are available and to confirm that those that you are using are being used correctly. USP documents that will be reviewed include:
- USP<51> Antimicrobial Effectiveness Testing
- USP<61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests
- USP<62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms
- USP<71> Sterility Tests
- USP<1072> Disinfectants and Antiseptics
- USP<1111> Microbiological Examination of Nonsterile Products
- USP<1112> Application of Water Activity Determination to Nonsterile Pharmaceutical Products
- USP<1113> Microbial Characterization, Identification, and Strain Typing
- USP<1116> Microbiological Control and Monitoring of Aseptic Processing Environments
Various team exercises will be conducted to allow the participants to use these USP documents to solve "real life" problems. Plan to bring a cross-functional group of your personnel to attend this invaluable two day seminar.
Learning Objectives:
- Understanding the various General and General Information USP Chapters that apply to microbiology
- The focus of the chapters to include those that primarily involve non-sterile and sterile applications
- Chapters that involve the environment
- Examining the changes within the various Chapters that have recently occurred and how to interpret them
- Review areas that are often overlooked
- Study issues that continue to exist between the USP, EP and JP (harmonization)
- Examine the new regulatory attitude that is occurring with non-sterile products
- What now constitutes a "specified" and "objectionable" microorganism
- Explore Form FDA 483s and Warning Letters for microbiological applications
Who Will Benefit:
- Manufacturing
- Product Development
- Project Management
- Quality Assurance
- Quality Control
- Regulatory Affairs
- Regulatory Compliance
Topic Background:
Microbiology plays a role throughout the manufacture of pharmaceutical products. Whether the final product is non-sterile or sterile, the bioburden exists within the raw materials, throughout the process and/or within the product's environment (water and HVAC) to the final product. A critical review of the overall microbiological process will determine whether the critical "in-process" points permit the final product to meet its acceptance criteria. In addition, any "objectionable" or "specified" microorganisms that may be encountered during the procurement of raw materials and the processing must be considered.
Whether you are testing a starting material (component), an in-process sample, the Active Pharmaceutical Ingredient (API), final product (whether non-sterile or sterile), the environment to include controlled and classified areas or the HVAC, you should be aware of the critical role the microorganisms play throughout. You should be aware of the various microbiological related documents, e.g., raw material sampling criteria, in-process, API, final product, environmental and utilities, (many of which have USP microbiological documents as the "bedrock" for building these documents, to determine whether the SOPs, validations as well as government and other regulatory body document requirements are being maintained to assure the control required to permit the final product to enter the marketplace as safe.
For Registration: